Covidien Launches Study To Expand Indication For Pipeline Aneurysm Device
This article was originally published in The Gray Sheet
Executive Summary
The firm hopes to support approval for use of the embolization device for smaller aneurysms and in more anatomical locations with data from its just-launched PREMIER trial. Also, Covidien announced the first patient in a new registry to track postmarket data, and hopefully support reimbursement, for its mechanical thrombectomy stroke devices including Solitaire 2.
You may also be interested in...
FDA Panel To Weigh In On Neuro Flow Diverter Device Studies
The agency's Neurological Devices Panel will provide recommendations on study design and data analysis issues for flow diverter devices for aneurysms in April.
Covidien Initiates Aneurysm Device Recall
The voluntary recall of Covidien’s Pipeline aneurysm embolization device and Alligator retrieval devices is expected to have a slight negative effect on earnings in the second half of the year, but the impact could increase if it takes longer than expected to replace the affected products, the firm suggested.
Covidien Plans April U.S. Launch Of Solitaire For Ischemic Strokes
Clot removal device gains 510(k) clearance earlier than expected, will compete with Stryker’s Merci clot retrieval system.